EQUILLIUM, INC. Cash and Restricted Cash
EQUILLIUM, INC. (EQ) had Cash and Restricted Cash of $28.51 million as of 2018-12-31, per its 10-K filed 2019-03-27.
Discontinued › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2019-03-27
- 2018-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $28.51M.
- 2018-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4.98M.
- 2017-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.10M.
- 2017-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $732.68K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2018-12-31 | $28.51M 10-K · filed 2019-03-27 |
| 2018-09-30 | $4.98M 10-Q · filed 2018-11-15 |
| 2017-12-31 | $7.10M 10-K · filed 2019-03-27 |
| 2017-09-30 | $732.68K 10-Q · filed 2018-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |